abstract |
Compounds according to formulas I and II are potent inhibitors of PSMA: I, or II The pharmaceutical composition may comprise a radionuclide and a complex comprising a compound of formula I or a compound of formula II. The method includes the use of a compound of formula I or a radionuclide complex of a compound of formula II for the treatment and diagnosis of diseases or disorders related to PSMA activity. |